Zunsemetinib
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases[1].
Product Specifications
CAS Number
[1640282-42-3]
Product Name Alternative
ATI-450; CDD-450
UNSPSC
12352005
Target
MAPKAPK2 (MK2)
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/zunsemetinib.html
Purity
99.99
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC1=CC(F)=CN=C1COC2=C(Cl)C(N(C3=CC(C4=NC(C(C)(C)O)=NC=C4)=NC=C3C)C(C)=C2)=O
Molecular Formula
C25H22ClF2N5O3
Molecular Weight
513.92
References & Citations
[1]Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor|[2]Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine|[3]Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215 (5) :1315-1325.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
